Drug Metabolism Handbook (eBook)
1064 Seiten
John Wiley & Sons (Verlag)
978-0-470-43925-8 (ISBN)
Ala F. Nassar, PhD, provides technical and operational leadership in characterizing in vitro and in vivo metabolites. His research focuses on understanding how structure modification can improve the ADME profile for new chemical entities as they advance towards clinical candidacy. Recently, he identified and patented pharmacologically active metabolites of Nexavar®. Dr. Nassar serves on the Editorial Board of Drug Metabolism Letters and The Open Drug Metabolism Journal and is also a reviewer for several other journals. Paul F. Hollenberg, PhD, is Maurice H. Seevers Collegiate Professor and Chair of Pharmacologyat The University of Michigan. His current research focuses on the relationship between thestructures of the active sites of cytochrome P450s and their catalytic function. Dr. Hollenbergwas cofounder and Associate Editor of Chemical Research in Toxicology and has served onnumerous editorial boards and review panels. Joann Scatina, PhD, has over twenty-four years of drug metabolism experience, and is currentlyVice President of the Drug Metabolism Division, Drug Safety and Metabolism, for WyethResearch. Dr. Scatina's research interests include identification of metabolites, metabolicpathways and enzymes responsible, in vitro-in vivo extrapolation, and prediction of druginteractions. She is a member of the American Society for Pharmacology and ExperimentalTherapeutics and the International Society for the Study of Xenobiotics (ISSX) and is currentlyserving on the Editorial Board of Drug Metabolism Reviews.
Preface.
List of Contributors.
Part I: Introduction.
1. Historical Perspective (Roberta S. King).
2. Factors Affecting Metabolism (Roberta S. King).
3. Biotransformation sin Drug Metabolism (Roberta S. King).
4.In Vivo Metabolite Kinetics (Zheng Yang).
5. Pharmacogenetics and Pharmacogenomics (Lilian G. Yengi).
6. Introduction to drug transporters (Louis Leung and Aram
Oganesian).
Part II: Technologies for In Vitro and In Vivo
Studies.
7. Automated Drug Screening for ADMET Properties (Melvin
Reichman and Helen Gill).
8. Mass Spectrometry (Thomas R. Sharp).
9. Approaches to Performing Metabolite Elucidation: One Key to
Success in Drug Discovery and Development (Ala F. Nassar).
10. Structural Modifications of Drug Candidates: How Useful Are
They in Improving Metabolic Stability of New Drugs? Part I:
Enhancing Metabolic Stability (Ala F. Nassar).
11. Structural Modifications of Drug Candidates: How Useful Are
They in Improving PK Parameters of New Drugs? Part II: Drug Design
Strategies (Ala F. Nassar).
12. Minimizing the Potential for Drug bioactivation of drug
Candidates to Success in Clinical Development (Ala F. Nassar).
13. Screening for reactive Metabolites Using Genotoxicity Arrays
and Enzyme/DNA Biocolloids (James F. Rusling, Eli G. Hvastkovs, and
John B. Schenkman).
Part III: Drug Interactions.
14. Enzyme Inhibition (Paul F. Hellenberg).
15. Evaluating and Predicting Human Cytochrome P450 Enzyme
Induction (Michael Sinz, Sean Kim, Stephen Ferguson, and Edward
LeCluyse).
16. An Introduction to Metabolic Reaction Phenotyping (Carl D.
Davis and A. David Rodrigues).
17. Nuclear receptor-Mediated Gene Regulation in Drug Metabolism
(Hongbing Wang and Wen Xie).
18. Characterization of Cytochrome P450 Mechanism-Based
Inhibition (Dan Rock and Larry C. Wienkers).
19. Clinical Drug-Drug Interactions.
20. Pharmaceutical Excipients in drug-Drug Interaction (Chuan
Chen and Abu J. M. Sadeque).
Part IV: Toxicity.
21. The Role of Drug Metabolism in Toxicity (Carl D. Davis and
Umesh M. Hanumegowda).
22. Allergic reactions to Drugs (Mark P. Grillo).
23. Chemical Mechanism in toxicology (Mark P. Grillo).
24. Mechanisms of Reproductive Toxicity (Aileen F. Keating and
Patricia B. Hoyer).
25. An Introduction to Toxicogenomics (Aaron L. Vollrath and
Christopher A. Bradfield).
26. Role of Bioactivation Reactions in Chemically Induced
Nephrotoxicity (Lawrence H. Lash).
Part V: Regulatory Perspectives.
27. Drug Metabolism in regulatory Guidances, clinical trials,
and Product Labeling (Mark N. Milton).
Index.
Erscheint lt. Verlag | 26.3.2009 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Gesundheitsfachberufe |
Medizin / Pharmazie ► Medizinische Fachgebiete | |
Naturwissenschaften ► Chemie | |
Schlagworte | Analytical Chemistry • Analytische Chemie • Chemie • Chemistry • Drug Discovery & Development • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Wirkstoffforschung u. -entwicklung |
ISBN-10 | 0-470-43925-4 / 0470439254 |
ISBN-13 | 978-0-470-43925-8 / 9780470439258 |
Haben Sie eine Frage zum Produkt? |
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich